JP2023504205A5 - - Google Patents

Info

Publication number
JP2023504205A5
JP2023504205A5 JP2022534665A JP2022534665A JP2023504205A5 JP 2023504205 A5 JP2023504205 A5 JP 2023504205A5 JP 2022534665 A JP2022534665 A JP 2022534665A JP 2022534665 A JP2022534665 A JP 2022534665A JP 2023504205 A5 JP2023504205 A5 JP 2023504205A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
corneal
composition according
lesions
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064042 external-priority patent/WO2021119146A1/en
Publication of JP2023504205A publication Critical patent/JP2023504205A/ja
Publication of JP2023504205A5 publication Critical patent/JP2023504205A5/ja
Pending legal-status Critical Current

Links

JP2022534665A 2019-12-09 2020-12-09 角膜病変の治療のための生体分子 Pending JP2023504205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945580P 2019-12-09 2019-12-09
US62/945,580 2019-12-09
PCT/US2020/064042 WO2021119146A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Publications (2)

Publication Number Publication Date
JP2023504205A JP2023504205A (ja) 2023-02-01
JP2023504205A5 true JP2023504205A5 (enExample) 2023-12-18

Family

ID=76330542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534665A Pending JP2023504205A (ja) 2019-12-09 2020-12-09 角膜病変の治療のための生体分子

Country Status (8)

Country Link
US (2) US20230019568A1 (enExample)
EP (1) EP4072578A4 (enExample)
JP (1) JP2023504205A (enExample)
CN (1) CN115038434A (enExample)
AU (1) AU2020402031A1 (enExample)
BR (1) BR112022011276A2 (enExample)
CA (1) CA3161233A1 (enExample)
WO (1) WO2021119146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311554A1 (en) * 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Similar Documents

Publication Publication Date Title
EP2482816B1 (en) Topical compositions of naltrexone for treating skin conditions
TWI250016B (en) Use of pramipexole for the treatment of addictive disorders
RU2095060C1 (ru) Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний
JPH06102622B2 (ja) 肥満の治療
KR100516676B1 (ko) 안면 수술에서의 레보부피바카인의 용도
JP2022523726A5 (enExample)
JP2006514092A5 (enExample)
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
JP2022525549A5 (enExample)
JP2022533968A5 (enExample)
Finlay Trigeminal trophic syndrome
Ishibashi Oral ketoconazole therapy for keratomycosis
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
SK287249B6 (sk) Liečivé produkty s cikatrizačným účinkom obsahujúce biguanidové deriváty
TW202617156A (zh) 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
JP2023508250A5 (enExample)
JP2025510311A5 (enExample)
TW200410683A (en) Medicament for preventing and/or treating peripheral neuropathies
KR20210044805A (ko) 사마귀의 치료
DE60017733T2 (de) Verwendung von riluzol zur behandlung multipler sklerose
US20110160166A1 (en) Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
RU2122844C1 (ru) Способ лечения герпетического кератита с изъязвлением
US20170258746A1 (en) Acetic acid/thymol compositions and their use in the treatment of onychomycosis
JPH0840902A (ja) 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物